Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 12/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208610 | 0.87 | L3MBTL1 (0.49) | HSPB1MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL6208856 | 0.83 | CYP11B2 (0.49) | HSPB1MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL4572853 | 0.83 | NR3C1 (0.56) | ALDH1A1LMNANR3C1PGR | |
| SCHEMBL6210172 | 0.82 | KDM4E (0.59) | NR3C1MEN1KMT2APGR | |
| SCHEMBL9449124 | 0.80 | HSPB1 (1.00) | HSPB1MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL6211088 | 0.80 | HSPB1 (0.55) | HSPB1MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL22530050 | 0.76 | HSPB1 (0.91) | HSPB1MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL29392306 | 0.76 | HSPB1 (0.91) | HSPB1MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL6209201 | 0.73 | SMO (0.49) | NR3C1PGR | |
| SCHEMBL22530033 | 0.73 | HSPB1 (0.70) | HSPB1MAPTNPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501833-B1 | N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6900201-B2 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040010141-A1 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010141-A1 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, MMP8, MMP2 | HSPB1 1770/4885MAPT 4657/4885NPSR1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.